Form 8-K - Current report:
SEC Accession No. 0001193125-26-257400
Filing Date
2026-06-04
Accepted
2026-06-04 16:10:06
Documents
11
Period of Report
2026-06-02
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K d69762d8k.htm   iXBRL 8-K 30955
  Complete submission text file 0001193125-26-257400.txt   146000

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA tenx-20260602.xsd EX-101.SCH 3203
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE tenx-20260602_lab.xml EX-101.LAB 17991
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tenx-20260602_pre.xml EX-101.PRE 11276
14 EXTRACTED XBRL INSTANCE DOCUMENT d69762d8k_htm.xml XML 3643
Mailing Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517
Business Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517 919-855-2100
TENAX THERAPEUTICS, INC. (Filer) CIK: 0000034956 (see all company filings)

EIN.: 262593535 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34600 | Film No.: 261065019
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)